GoAI
Get started
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp.

LEXX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$10.915

−$0.355 · -3.15%

Aug 21, 4:00 PM ET

LEXX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

57

Fair Value

Momentum

30

Weakening

Sentiment

44

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA
CEO
Richard C. Christopher
Listed since
Jan 12, 2021
Employees
7

Market position

Day range

Current $10.915

52-week range

Current $10.915

Open
$10.85
Previous close
$11.27
Volume
8.92K
0.62× average
Average volume
14.39K
Average daily volume
Market cap
18.04M USD
Beta
0.34
Market reference 1
50-day average
$8.2688
+32.00% above average
200-day average
$11.0843
-1.53% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
14.15M USD
P/E (TTM)
-2.05×
P/B (TTM)
3.81×
P/S (TTM)
92.97×
EV / EBITDA
-1.2×
Earnings yield
-75.14%
Free cash flow yield
-66.13%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-3973.16%
Net margin
-3985.58%
Return on equity
-398.10%
Return on assets
-285.07%
Return on invested capital
-438.07%

Financial health

Debt / equity
0.02×
Current ratio
2.32×
Altman Z-score
0.33
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends404%-814%-2033%-3251%Gross margin, FY2021: 75.74%Gross margin, FY2022: 71.87%Gross margin, FY2023: 86.07%Gross margin, FY2024: 98.96%Gross margin, FY2025: 99.61%Operating margin, FY2021: -786.85%Operating margin, FY2022: -2591.67%Operating margin, FY2023: -2888.50%Operating margin, FY2024: -1239.16%Operating margin, FY2025: -1683.01%Net margin, FY2021: -557.19%Net margin, FY2022: -2846.28%Net margin, FY2023: -2946.36%Net margin, FY2024: -1248.25%Net margin, FY2025: -1686.00%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 75.74%. Gross margin FY2022 71.87%. Gross margin FY2023 86.07%. Gross margin FY2024 98.96%. Gross margin FY2025 99.61%. Operating margin FY2021 -786.85%. Operating margin FY2022 -2591.67%. Operating margin FY2023 -2888.50%. Operating margin FY2024 -1239.16%. Operating margin FY2025 -1683.01%. Net margin FY2021 -557.19%. Net margin FY2022 -2846.28%. Net margin FY2023 -2946.36%. Net margin FY2024 -1248.25%. Net margin FY2025 -1686.00%.

Income trends

Revenue

705.92K USD+52.05%

Operating income

−11.88M USD-106.51%

Net income

−11.9M USD-105.37%
Income trends across reported periods1.99M USD−3.06M USD−8.11M USD−13.16M USDRevenue, FY2021: 722.74K USDRevenue, FY2022: 255.4K USDRevenue, FY2023: 226.21K USDRevenue, FY2024: 464.28K USDRevenue, FY2025: 705.92K USDOperating income, FY2021: −5.69M USDOperating income, FY2022: −6.62M USDOperating income, FY2023: −6.53M USDOperating income, FY2024: −5.75M USDOperating income, FY2025: −11.88M USDNet income, FY2021: −4.03M USDNet income, FY2022: −7.27M USDNet income, FY2023: −6.66M USDNet income, FY2024: −5.8M USDNet income, FY2025: −11.9M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 722.74K USD. Revenue FY2022 255.4K USD. Revenue FY2023 226.21K USD. Revenue FY2024 464.28K USD. Revenue FY2025 705.92K USD. Operating income FY2021 −5.69M USD. Operating income FY2022 −6.62M USD. Operating income FY2023 −6.53M USD. Operating income FY2024 −5.75M USD. Operating income FY2025 −11.88M USD. Net income FY2021 −4.03M USD. Net income FY2022 −7.27M USD. Net income FY2023 −6.66M USD. Net income FY2024 −5.8M USD. Net income FY2025 −11.9M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue705.92K USD464.28K USD226.21K USD255.4K USD722.74K USD
Cost of goods sold2.72K USD4.82K USD31.5K USD71.84K USD175.35K USD
Gross profit703.2K USD459.46K USD194.71K USD183.56K USD547.39K USD
Research and development8.24M USD2.36M USD3.67M USD1.84M USD1.26M USD
Selling, general, and administrative4.35M USD3.85M USD3.06M USD4.96M USD4.97M USD
Operating expenses12.58M USD6.21M USD6.73M USD6.8M USD6.23M USD
Interest income3.02K USD14.31K USD43.19K USD——
Depreciation and amortization87.83K USD76.15K USD145.4K USD102.72K USD147.6K USD
Operating income−11.88M USD−5.75M USD−6.53M USD−6.62M USD−5.69M USD
Net income−11.9M USD−5.8M USD−6.66M USD−7.27M USD−4.03M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-6.55%
11 comparable reports
Latest EPS result
-1.2
Estimate -0.9 · Miss by 33.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.77-1.62-2.48-3.33Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Jan 10, 2025: actual -2.4, estimate -1.8, surprise -33.33%, Miss. Q2 2025, reported Apr 14, 2025: actual -2.25, estimate -2.4, surprise +6.25%, Beat. Q3 2025, reported Jul 14, 2025: actual -3.15, estimate -2.25, surprise -40.00%, Miss. Q4 2025, reported Nov 26, 2025: actual -2.1, estimate -2.4, surprise +12.50%, Beat. Q1 2026, reported Jan 13, 2026: actual -1.05, estimate -1.95, surprise +46.15%, Beat. Q2 2026, reported Apr 13, 2026: actual -0.9, estimate -1.05, surprise +14.29%, Beat. Q3 2026, reported Jul 13, 2026: actual -1.2, estimate -0.9, surprise -33.33%, Miss. Q4 2026, reported Oct 28, 2026: actual —, estimate -0.9, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates214.4K148.6K82.8K17KQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26EstimateQ2 '26MissQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Jan 10, 2025: actual 184K USD, estimate 100K USD, surprise +84.00%, Beat. Q2 2025, reported Apr 14, 2025: actual 174K USD, estimate 150K USD, surprise +16.00%, Beat. Q3 2025, reported Jul 14, 2025: actual 174K USD, estimate 137K USD, surprise +27.01%, Beat. Q4 2025, reported Nov 26, 2025: actual 200K USD, estimate 137K USD, surprise +45.99%, Beat. Q1 2026, reported Jan 13, 2026: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q2 2026, reported Apr 13, 2026: actual 20K USD, estimate 50K USD, surprise -60.00%, Miss. Q3 2026, reported Jul 13, 2026: actual —, estimate 50K USD, surprise —, Comparison unavailable. Q4 2026, reported Oct 28, 2026: actual —, estimate 50K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$1.50

86.26% downside
Past 12 months12-month forecastHigh $1.50Average $1.50Low $1.50

Recent analyst actions

2 institutions
Maxim GroupmaintainBuy

LEXX news

benzinga.com

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here's what investors need to know.

Read source
accessnewswire.com

Lexaria Enters a Material Transfer Agreement With PegBio

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer…

Read source
thenewswire.com

Lexaria Enters a Material Transfer Agreement with PegBio

Kelowna, British Columbia – TheNewswire - August 13, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it has entered into a…

Read source
thenewswire.com

Lexaria Announces Effective Date for Reverse Stock Split

Kelowna, British Columbia – TheNewswire - July 30, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it intends to effect a…

Read source
accessnewswire.com

Lexaria Announces Effective Date for Reverse Stock Split

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock…

Read source
accessnewswire.com

Lexaria Updates Business Development

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings…

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 3, 2026

1:15

Stock split

Effective Jan 12, 2021

1:30

Stock split

Effective Dec 16, 2015

11:10

Stock split

Effective Jun 30, 2009

1:4

LEXX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LEXX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
116.69K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research LEXX

research.disclaimer